Korean J Cerebrovasc Dis.
2001 Mar;3(1):81-82.
A Case of Aplastic Anemia Associated with Ticlopidine
- Affiliations
-
- 1Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea. KS1007@cmc.cuk.ac.kr
Abstract
- Aplastic anemia is a rare side-effect associated with ticlopidine therapy. We report one case of severe aplastic anemia developed after the use of ticlopidine. A 72-year-old woman took ticlopidine at 500 mg/day to prevent a secondary stroke. Forty days after starting ticlopidine, she developed general weakness and nausea. She showed pancytopenia and was diagnosed as aplastic anemia, confirmed by bone marrow examination. Twelve days after the withdrwal of ticlopidine, the hematologic parameters improved. Physicians are reminded that complete blood cell counts and white blood cell count differentials should be monitored every 2 weeks in ticlopidine users during the first 3 months of treatment.